Please provide your email address to receive an email when new articles are posted on . Patients were treated with intravenous ertapenem for an average of 13.1 weeks. During a 7-week, posttherapy ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr.

Please provide your email address to receive an email when new articles are posted on . A trial that evaluated three alternative treatments for anogenital gonorrhea found that a single dose of ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the availability in the United States of Ertapenem for Injection in a 1 gram vial presentation. The new product is the generic ...

Aurobindo Pharma Limited today said it received final approval from the US Foodand Drug Administration (USFDA) to manufacture and market Ertapenem Injection 1 g/vial. Aurobindo's Ertapenem injection ...

FDA Approves New Indication for INVANZ (ertapenem) for the Prevention of Surgical Site Infections (SSI) following Elective Colorectal Surgery in Adults WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck ...

Findings showed that the trial failed to demonstrate noninferiority, with a responder rate of 67.8% for sulopenem at the test of cure visit compared with 73.9% for ertapenem (difference of -6.1%; [95% ...

Dr Reddy's Laboratories Ltd, on Wednesday, announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of Invanz approved by the US Food and Drug Administration ...

(RTTNews) - Dr. Reddy's Laboratories (RDY) Wednesday announced the launch of Ertapenem for Injection 1 g/vial, a generic version of Invanz, in the U.S. market. Dr. Reddy's Ertapenem for Injection, 1 g ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr.